PATENT CLAIM ANALYSIS

Application Number: 16053540
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "174100"]

Abstract:
The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Claim (Index 1):
A combination, comprising:\n (i) an effective amount of a PD-L/PD-1 Axis antagonist antibody; and (ii) an effective amount of an immunotherapeutic, wherein the immunotherapeutic is 4-amino-2-(ethoxymethyl)-a,a-di-methyl-1H-imidazo[4,5-c]quinoline-1-ethanol; wherein the PD-L/PD-1 Axis antagonist antibody and the immunotherapeutic are not covalently linked to each other.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 96.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15110685', '15793820', '15110690', '15849436', '15849470']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7175761615237047
- 35 USC 102 Novelty (BERT): 0.5400800202139311
- Combined Prediction Score: 0.6998265473927274
- Mean Citation Score: 340.2965880000001
- Max Citation Score: 374.08197
- Similarity Product: 220.15355796454844

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test